The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
Abstract
Treating patients who have cancer with vaccines that stimulate a targeted immune response is conceptually appealing, but cancer vaccine trials have not been successful in late-stage patients with treatment-refractory tumours 1,2. We are testing melanoma FixVac (BNT111)-an intravenously administered liposomal RNA (RNA-LPX) vaccine, which targets four non-mutated, tumour-associated antigens that are prevalent in melanoma-in an ongoing, first-in-human, dose-escalation phase I trial in patients with advanced melanoma (Lipo-MERIT trial, ClinicalTrials.gov identifier NCT02410733). We report here data from an exploratory interim analysis that show that melanoma FixVac, alone or in combination with blockade of the checkpoint inhibitor PD1, mediates durable objective responses in checkpoint-inhibitor (CPI)-experienced patients with unresectable melanoma. Clinical responses are accompanied by the induction of strong CD4+ and CD8+ T cell immunity against the vaccine antigens. The antigen-specific cytotoxic T-cell responses in some responders reach magnitudes typically reported for adoptive T-cell therapy, and are durable. Our findings indicate that RNA-LPX vaccination is a potent immunotherapy in patients with CPI-experienced melanoma, and suggest the general utility of non-mutant shared tumour antigens as targets for cancer vaccination.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinical trials of mRNA-based immunotherapeutics encoding unmutated full-length TAAs in checkpoint inhibitor-treated melanoma [18] and individualised mRNA-based immunotherapeutics encoding patient-specific mutated tumour neoantigens in pancreatic and lung cancer [19, 20] have shown encouraging results.”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [18]
In the citing paper
“Previous studies have demonstrated that the use of BNT111 alone or in combination with PD-1 antibody can activate tumor antigen-specific CD4+ and CD8+ T cells and elicit durable immune responses.345,350–352”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [345]
In the citing paper
“For example, FixVac, which was developed based on the RNA-LPX formulation, is a systemic mRNA vaccine encoding four non-mutated antigens of melanoma200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
In the citing paper
“After the eighth immunization, more than 75% of patients generated immune responses against at least one tumour-associated antigen, and CD8+ T cells played a major role in high-magnitude T cell responses200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
In the citing paper
“Moreover, a combination of FixVac/anti-programmed cell death protein 1 (PD1) antibody augmented the antitumour effect of FixVac, resulting in a >35% tumour regression rate in immune checkpoint inhibitor-experienced patients200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
In the citing paper
“The interim analysis from the phase I trial (NCT02410733) showed that the metabolic activity of the spleen increased post the sixth immunization, indicating targeted delivery of FixVac and activation of resident immune cells200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Self-citationSystemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Self-citationMiXCR: software for comprehensive adaptive immunity profiling
Bolotin, D. A., Poslavskii, S., Mitrophanov, I., Shugay, M., Mamedov, I. Z., Putintseva, E. V., & Chudakov, D. M. (2015) · Nature Methods · doi:10.1038/nmeth.3364 · Cited by 1,730
Cancer/testis antigens, gametogenesis and cancer
Simpson, A. J. G., Caballero, O. L., Jungbluth, A. A., Chen, Y., & Old, L. J. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1669 · Cited by 1,587
Cheever, M. A., Allison, J. P., Ferris, A. S., Finn, O. J., Hastings, B. M., Hecht, T. T., Mellman, I., Prindiville, S. A., Viner, J. L., Weiner, L. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0737 · Cited by 1,388
Cited by
Sorted by citations
Items 301–400 of 1,000
CircRNAs: functions and emerging roles in cancer and immunotherapy
Wang, Y., Cui, Y., Li, X., Jin, S., Wang, H., Gaipl, U. S., Ma, H., Wang, S., & Zhou, J. (2025) · BMC Medicine · doi:10.1186/s12916-025-04306-5 · Cited by 35
Nanomedicine for advanced cancer immunotherapy
Diep, Y. N., Kim, T. J., Cho, H., & Lee, L. P. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.10.004 · Cited by 35
Current state of, prospects for, and obstacles to mRNA vaccine development
Aljabali, A. A. A., Bashatwah, R. M., Obeid, M. A., Mishra, V., Mishra, Y., Serrano‐Aroca, Á., Lundstrom, K. H., & Tambuwala, M. M. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103458 · Cited by 35
Nanotechnology-Based Approaches to Promote Lymph Node Targeted Delivery of Cancer Vaccines
He, R., Zang, J., Zhao, Y., Dong, H., & Li, Y. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c01274 · Cited by 34
Spleen-targeted nanosystems for immunomodulation
Wang, F., Lou, J., Gao, X., Zhang, L., Sun, F., Wang, Z., Ji, T., & Qin, Z. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101943 · Cited by 36
Advances and prospects of mRNA vaccines in cancer immunotherapy
Liu, Y., Yan, Q., Zeng, Z., Fan, C., & Xiong, W. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189068 · Cited by 33
Nucleic acid drug and delivery techniques for disease therapy: Present situation and future prospect
Wang, T., Tang, Y., Tao, Y., Zhou, H., & Ding, D. (2024) · Interdisciplinary medicine · doi:10.1002/inmd.20230041 · Cited by 33
mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends
Gao, Y., Yang, L., Li, Z., Peng, X., & Li, H. (2024) · Biomarker Research · doi:10.1186/s40364-024-00644-3 · Cited by 34
Nano‐Oncologicals: A Tortoise Trail Reaching New Avenues
Dacoba, T. G., Anthiya, S., Berrecoso, G., Fernández‐Mariño, I., Fernández‐Varela, C., Crecente‐Campo, J., Teijeiro‐Osorio, D., Torres, F., & Alonso, M. J. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202009860 · Cited by 34
Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines
Abbasi, S., & Uchida, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050644 · Cited by 33
The development and improvement of ribonucleic acid therapy strategies
Zhao, Y., Shu, R., & Liu, J. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.09.002 · Cited by 33
The Current Landscape of mRNA Vaccines Against Viruses and Cancer–A Mini Review
Ladak, R. J., He, A. J., Huang, Y.-H., & Ding, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.885371 · Cited by 35
Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity
Liu, W., Alameh, M., Yang, J. F., Xu, J. R., Lin, P. J. C., Tam, Y. K., Weissman, D., & You, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314504 · Cited by 33
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
Middelburg, J., Sluijter, M., Schaap, G., Göynük, B., Lloyd, K. A., Ovcinnikovs, V., Zom, G. G., Marijnissen, R. J., Groeneveldt, C., Griffioen, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44308-6 · Cited by 32
Advances in cell therapy: progress and challenges in hematological and solid tumors
D'Avanzo, C., Blaeschke, F., Lysandrou, M., Ingelfinger, F., & Zeiser, R. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.10.016 · Cited by 32
Circular RNA vaccines: Pioneering the next-gen cancer immunotherapy
Das, U., Banerjee, S., Sarkar, M., Fathah Muhammad, L., Soni, T. K., Saha, M., Pradhan, G., & Chatterjee, B. (2024) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2024.11.003 · Cited by 37
Leveraging mRNA technology for antigen based immuno-oncology therapies
Floudas, C. S., Sarkizova, S., Ceccarelli, M., & Zheng, W. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010569 · Cited by 32
Human TYRP1: Two functions for a single gene?
Gautron, A., Migault, M., Bachelot, L., Corre, S., Galibert, M., & Gilot, D. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12951 · Cited by 34
Grabowska, J. A., Affandi, A. J., van Dinther, D., Twilhaar, M. K. N., Olesek, K., Hoogterp, L., Ambrosini, M., Heijnen, D. A. M., Klaase, L., Hidalgo, A., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.029 · Cited by 33
Sohi, A. N., Kiani, J., Arefian, E., Khosrojerdi, A., Fekrirad, Z., Ghaemi, S., Zim, M. K., Jalili, A., Bostanshirin, N., & Soleimani, M. (2021) · Vaccines · doi:10.3390/vaccines9091007 · Cited by 32
Antigen discovery for the development of cancer immunotherapy
Ahn, R., Cui, Y., & White, F. M. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101733 · Cited by 33
Breast cancer immunopeptidomes contain numerous shared tumor antigens
Kina, E., Laverdure, J., Durette, C., Lanoix, J., Courcelles, M., Zhao, Q., Apavaloaei, A., Larouche, J., Hardy, M., Vincent, K., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci166740 · Cited by 31
Miao, H., Yuan, F., Pan, C.-X., Yang, H., Wang, Z., Qi, Y., Wu, Y. Z., Zhang, Y., Liu, F., Huang, H., et al. (2025) · Medicine Plus · doi:10.1016/j.medp.2025.100087 · Cited by 33
Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma
Comito, F., Pagani, R., Grilli, G., Sperandi, F., Ardizzoni, A., & Melotti, B. (2022) · Cancers · doi:10.3390/cancers14020271 · Cited by 32
What’s next for cancer vaccines
Adamik, J., & Butterfield, L. H. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo4632 · Cited by 31
Path towards mRNA delivery for cancer immunotherapy from bench to bedside
Chen, W., Zhu, Y., He, J., & Sun, X. (2023) · Theranostics · doi:10.7150/thno.89247 · Cited by 33
Santiago-Sánchez, G. S., Fabian, K. P., & Hodge, J. W. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2308097 · Cited by 31
Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It
Zielińska, M. K., Ciążyńska, M. A., Sulejczak, D., Rutkowski, P. L., & Czarnecka, A. M. (2025) · Biomolecules · doi:10.3390/biom15020269 · Cited by 30
Nano Approaches to Nucleic Acid Delivery: Barriers, Solutions, and Current Landscape
Gonzalez, J. C., Park, K. W., Evans, D. B., Sharma, R. B., Sahaym, O., Gopalakrishnan, S., Dar, A. I., Valdez, T. A., & Sharma, A. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70010 · Cited by 31
Li, M., Wang, Z., Xie, C., & Xia, X. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.011 · Cited by 30
Recent Advances in Cancer Immunotherapy Delivery Modalities
Muthukutty, P., Woo, H. Y., Murali, R., & Yoo, S. Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020504 · Cited by 31
Cancer testis antigen subfamilies: Attractive targets for therapeutic vaccine (Review)
Ren, S., Zhang, Z., Li, M., Wang, D., Guo, R., Fang, X., & Chen, F. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5519 · Cited by 30
Improved cancer immunotherapy strategies by nanomedicine
Guo, S., Feng, J., Li, Z., Yang, S., Qiu, X., Xu, Y., & Shen, Z. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1873 · Cited by 29
Strategies for Improving CAR T Cell Persistence in Solid Tumors
Wittling, M. C., Cole, A. C., Brammer, B., Diatikar, K. G., Schmitt, N. C., & Paulos, C. M. (2024) · Cancers · doi:10.3390/cancers16162858 · Cited by 31
Immunomodulating Therapies in Breast Cancer—From Prognosis to Clinical Practice
Schmidt, M., & Heimes, A.-S. (2021) · Cancers · doi:10.3390/cancers13194883 · Cited by 28
Recent Advances in Delivery Systems for Genetic and Other Novel Vaccines
Huang, S., Zhu, Y., Zhang, L., & Zhang, Z. (2021) · Advanced Materials · doi:10.1002/adma.202107946 · Cited by 28
Tumor antigen-loaded AAV vaccine drives protective immunity in a melanoma animal model
Krotova, K. Y., Kuoch, H., Caine, C., & Aslanidi, G. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.01.006 · Cited by 28
Counteracting Immunosenescence—Which Therapeutic Strategies Are Promising?
Hieber, C., Grabbe, S., & Bros, M. (2023) · Biomolecules · doi:10.3390/biom13071085 · Cited by 30
Self-citationNanomedicine: A pragmatic approach for tackling melanoma skin cancer
Prajapat, V. M., Mahajan, S., Paul, P., Aalhate, M., Mehandole, A., Madan, J., Dua, K., Chellappan, D. K., Singh, S. K., & Singh, P. K. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104394 · Cited by 28
He, Y., Cheng, C., Liu, Y., Chen, F., Chen, Y., Yang, C., Zhao, Z., Dawulieti, J., Shen, Z., Zhang, Y., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c07943 · Cited by 28
Zhang, J., Joshua, A. M., Li, Y., O’Meara, C. H., Morris, M. J., & Khachigian, L. M. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216633 · Cited by 27
Li, C., Clauson, R. M., Bugada, L. F., Ke, F., He, B., Yu, Z., Chen, H., Jacobovitz, B., Hu, H., Chuikov, P., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c13038 · Cited by 27
Nanoparticle Retinoic Acid-Inducible Gene I Agonist for Cancer Immunotherapy
Wang-Bishop, L., Wehbe, M., Pastora, L. E., Yang, J., Kimmel, B. R., Garland, K. M., Becker, K. W., Carson, C. S., Roth, E. W., Gibson-Corley, K. N., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c06225 · Cited by 27
Protein isoform-centric therapeutics: expanding targets and increasing specificity
Kjer-Hansen, P., Phan, T. G., & Weatheritt, R. J. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01025-z · Cited by 27
Keshari, S., Shavkunov, A. S., Miao, Q., Saha, A., Minowa, T., Molgora, M., Williams, C. D., Chaib, M., Highsmith, A. M., Pineda, J. E., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114875 · Cited by 28
mRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy
Shariati, A., Khani, P., Nasri, F., Afkhami, H., Khezrpour, A., Kamrani, S., Shariati, F. S., Alavimanesh, S., & Modarressi, M. H. (2024) · Biomarker Research · doi:10.1186/s40364-024-00692-9 · Cited by 27
Application of mRNA Technology in Cancer Therapeutics
Eralp, Y. (2022) · Vaccines · doi:10.3390/vaccines10081262 · Cited by 27
Chung, S., Lee, C. M., & Zhang, M. (2022) · Nanoscale Horizons · doi:10.1039/d2nh00289b · Cited by 28
Engineering an active immunotherapy for personalized cancer treatment and prevention of recurrence
Wu, K., Lyu, F., Wu, S.-Y., Sharma, S., Deshpande, R. P., Tyagi, A., Zhao, D., Xing, F., Singh, R. N., & Watabe, K. (2023) · Science Advances · doi:10.1126/sciadv.ade0625 · Cited by 27
Vaccinating against cancer: getting to prime time
Chang, R., Gulley, J. L., & Fong, L. H. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006628 · Cited by 28
Han, R., Rao, X., Zhou, H., & Lu, L. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s461289 · Cited by 26
Chi, W.-Y., Hu, Y., Huang, H., Kuo, H., Lin, S., Kuo, C.-T. J., Tao, J., Fan, D., Huang, Y.-M., Wu, A. A., et al. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01082-x · Cited by 27
CAR-T cell therapy for breast cancer: Current status and future perspective
Buono, G., Capozzi, M., Caputo, R., Lauro, V. D., Cianniello, D., Piezzo, M., Cocco, S., Martinelli, C., Verrazzo, A., Tafuro, M., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102868 · Cited by 27
Leveraging Artificial Intelligence for Neoantigen Prediction
Zeng, J., Lin, Z., Zhang, X., Zheng, T., Xu, H., & Liu, T. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-2553 · Cited by 26
Cellular Cancer Immunotherapy Development and Manufacturing in the Clinic
Fenton, G. A., & Mitchell, D. A. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2257 · Cited by 26
Cancer vaccines: from an immunology perspective
Makker, S., Galley, C., & Bennett, C. L. (2023) · Immunotherapy Advances · doi:10.1093/immadv/ltad030 · Cited by 27
Cui, G., Sun, Y., Qu, L., Shen, C., Sun, Y., Meng, F., Zheng, Y., & Zhong, Z. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202303690 · Cited by 25
Xu, Z. C., Xiao, Z.-X., Wang, J., Qiu, H.-W., Cao, F., Zhang, S., Xu, Y.-D., Lei, H., Xia, H., He, Y.-R., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2373526 · Cited by 25
Schmitt, S., Huppertsberg, A., Klefenz, A., Kaps, L., Mailänder, V., Schuppan, D., Butt, H., Nuhn, L., & Koynov, K. (2022) · Biomacromolecules · doi:10.1021/acs.biomac.1c01407 · Cited by 26
RNA in Cancer Immunotherapy: Unlocking the Potential of the Immune System
de Mey, W., Esprit, A., Thielemans, K., Breckpot, K., & Franceschini, L. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3304 · Cited by 27
Vaccine Therapy in Non-Small Cell Lung Cancer
García-Pardo, M., Gorría, T., Malenica, I., Corgnac, S., Teixidó, C., & Mezquita, L. (2022) · Vaccines · doi:10.3390/vaccines10050740 · Cited by 25
Cirella, A., Bolaños, E., Trani, C. A. D., de Andrea, C. E., Sánchez‐Gregorio, S., Etxeberría, I., González-Gomariz, J., Olivera, I., Brocco, D., Glez‐Vaz, J., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0373 · Cited by 25
The Novelty of mRNA Viral Vaccines and Potential Harms: A Scoping Review
Halma, M. T. J., Rose, J., Jenks, A., & Lawrie, T. A. (2023) · J — Multidisciplinary Scientific Journal · doi:10.3390/j6020017 · Cited by 25
Shi, L. D., Yang, J., Nie, Y., Huang, Y., & Gu, H. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301261 · Cited by 25
İmani, S., Tagit, O., & Pichon, C. (2024) · npj Vaccines · doi:10.1038/s41541-024-00807-1 · Cited by 25
RetractedAdvances in Engineering Circular RNA Vaccines
Zhang, Z., Fu, Y., Ju, X., Zhang, F., Zhang, P., & He, M. (2024) · Pathogens · doi:10.3390/pathogens13080692 · Cited by 27
Cancer mRNA vaccines: clinical application progress and challenges
Li, H., Min, L., Du, H., Wei, X., & Tong, A. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217752 · Cited by 26
Recent Advances in Lipid Nanoparticles: Nucleic Acid Therapeutics and Targeting Strategies
Sarmah, S., Baidya, S., & De, M. (2025) · Small · doi:10.1002/smll.202506812 · Cited by 25
Walle, T., Bajaj, S., Kraske, J. A., Rösner, T., Cussigh, C. S., Kälber, K. A., Müller, L. J., Strobel, S. B., Burghaus, J., Kallenberger, S. M., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00398-7 · Cited by 24
Self-citationde Beijer, M. T. A., Bezstarosti, K., Luijten, R. J., Doff, W. A. S., Boor, P. P. C., Pieterman, R. F. A., Bouzid, R., Biesta, P. J., IJzermans, J. N. M., Doukas, M., et al. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100576 · Cited by 24
Lipid nanoparticles technology in vaccines: Shaping the future of prophylactic medicine
Abdellatif, A. A. H., Younis, M. A., Alsowinea, A. F., Abdallah, E. M., Abdel‐Bakky, M. S., Al-Subaiyel, A., Hassan, Y. A., & Tawfeek, H. M. (2022) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2022.113111 · Cited by 24
Advancing Cancer Immunotherapy: The Potential of mRNA Vaccines As a Promising Therapeutic Approach
Goyal, F., Chattopadhyay, A., Navik, U., Jain, A., Reddy, P. H., Bhatti, G. K., & Bhatti, J. S. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300255 · Cited by 25
Nanocarriers of antigen proteins for vaccine delivery
Chaves, L. L., Dourado, D., Prunache, I.-B., da Silva, P. M. M., Lucena, G. T. D. S., de Souza, Z. C., de Moura, P. M. M. F., Bordallo, H. N., Formiga, F. R., & Rebouças, J. D. S. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124162 · Cited by 25
Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer
Saillard, M., Cenerenti, M., Romero, P., & Jandus, C. (2021) · Vaccines · doi:10.3390/vaccines9050454 · Cited by 23
Ma, M., Li, X., Zhong, M., Li, X., Yu, J., Wang, Z., Lv, Q., Li, X., He, Z., Liu, H., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c15442 · Cited by 23
Barazandeh, S., Özden, F., Hınçer, A., Şeker, U. Ö. Ş., & Çiçek, A. E. (2024) · Bioinformatics Advances · doi:10.1093/bioadv/vbaf134 · Cited by 24
Andac-Aktas, A. B., & Calibasi‐Kocal, G. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1687556 · Cited by 25
Zhang, S.-W., Wang, H., Ding, X., Xiao, Y.-L., Shao, Z.-M., You, C., Gu, Y., & Jiang, Y. (2022) · Fundamental Research · doi:10.1016/j.fmre.2022.03.009 · Cited by 23
Exosomal and Non-Exosomal MicroRNAs: New Kids on the Block for Cancer Therapy
Syed, S. N., & Brüne, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094493 · Cited by 25
mRNA delivery technologies: Toward clinical translation
Gómez-Aguado, I., Rodríguez-Castejón, J., Beraza-Millor, M., Rodríguez‐Gascón, A., del Pozo‐Rodríguez, A., & Solinís, M. Á. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.010 · Cited by 23
De, A., & Ko, Y. T. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2153832 · Cited by 24
Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy
Liu, G., & Luo, P. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1208788 · Cited by 25
Fang, X.-L., Cao, X.-P., Xiao, J., Hu, Y., Chen, M., Raza, H. K., Wang, H.-Y., He, X., Gu, J., & Zhang, K.-J. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2024.2309563 · Cited by 23
Prospects and Challenges in Developing mRNA Vaccines for Infectious Diseases and Oncogenic Viruses
Kutikuppala, L. V. S., Kourampi, I., Kanagala, R. S. D., Bhattacharjee, P., & Boppana, S. H. (2024) · Medical Sciences · doi:10.3390/medsci12020028 · Cited by 24
Advancing mRNA Therapeutics: The Role and Future of Nanoparticle Delivery Systems
Li, J., Zhang, Y., Yang, Y., & Sun, T. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00276 · Cited by 24
Cancer immunotherapy and its facilitation by nanomedicine
Sui, C., Wu, H., Li, X., Wang, Y., Wei, J., Yu, J., & Wu, X. (2024) · Biomarker Research · doi:10.1186/s40364-024-00625-6 · Cited by 23
Controlling Antigen Fate in Therapeutic Cancer Vaccines by Targeting Dendritic Cell Receptors
Wijfjes, Z., van Dalen, F. J., Gall, C. M. L., & Verdoes, M. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00330 · Cited by 23
The dual role of IgG4 in immunity: bridging pathophysiology and therapeutic applications
Piseddu, I., Mayerle, J. V., Mahajan, U. M., & Boehmer, D. F. R. (2025) · Gut · doi:10.1136/gutjnl-2025-335375 · Cited by 22
Younis, M. A., Sato, Y., Kimura, S., & Harashima, H. (2025) · RSC Pharmaceutics · doi:10.1039/d5pm00079c · Cited by 24
mRNA Vaccines: Current Applications and Future Directions
Li, J., Liu, Y., Dai, J., Li, Y., Xiong, F., Xia, J., Jin, J., Wu, Y., & Peng, X. (2025) · MedComm · doi:10.1002/mco2.70434 · Cited by 27
Paijens, S. T., Vledder, A., Loiero, D., Duiker, E. W., Bart, J., Hendriks, A. M., Jalving, M., Workel, H. H., Hollema, H., Werner, N., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1935104 · Cited by 22
Harnessing dendritic cells for innovative therapeutic cancer vaccines
Plumas, J. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000815 · Cited by 22
Lipid‐based nucleic acid therapeutics with in vivo efficacy
Sufian, M. A., & Ilies, M. A. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1856 · Cited by 23
mRNA-Based Approaches to Treating Liver Diseases
Cacicedo, M. L., Limeres, M. J., & Gehring, S. (2022) · Cells · doi:10.3390/cells11203328 · Cited by 23
Advanced Biomaterials with Intrinsic Immunomodulation Effects for Cancer Immunotherapy
Chen, W., Li, C., & Jiang, X. (2023) · Small Methods · doi:10.1002/smtd.202201404 · Cited by 22
The clinical progress and challenges of mRNA vaccines
Yu, M., Wang, N., Zhu, J., & Lin, Y. (2023) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1894 · Cited by 23
Immunotherapy in Melanoma: Recent Advancements and Future Directions
Mooradian, M. J., & Sullivan, R. J. (2023) · Cancers · doi:10.3390/cancers15164176 · Cited by 23
Challenges and opportunities in the development of mucosal mRNA vaccines
Kirtane, A. R., Tang, C., Freitas, D., Bernstock, J. D., & Traverso, G. (2023) · Current Opinion in Immunology · doi:10.1016/j.coi.2023.102388 · Cited by 24
Ren, D., Xiong, S., Ren, Y., Yang, X., Zhao, X., Jin, J., Xu, M., Liang, T., Guo, L., & Weng, L. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.04.054 · Cited by 23
Das, R., Ge, X., Fei, F., Parvanian, S., Weissleder, R., & Garris, C. (2024) · Small Methods · doi:10.1002/smtd.202400633 · Cited by 22
Metadata
- Authors
- Sahin, U., Oehm, P., Derhovanessian, E., Jabulowsky, R. A., Vormehr, M., Gold, M., Maurus, D., Schwarck-Kokarakis, D., Kuhn, A. N., Omokoko, T., Kranz, L. M., Diken, M., Kreiter, S., Haas, H., Attig, S., Rae, R., Cuk, K., Kemmer-Brück, A., Breitkreuz, A., Tolliver, C., Caspar, J., Quinkhardt, J., Hebich, L., Stein, M., Hohberger, A., Vogler, I., Liebig, I., Renken, S., Sikorski, J., Leierer, M., Müller, V., Mitzel-Rink, H., Miederer, M., Huber, C., Grabbe, S., Utikal, J., Pinter, A., Kaufmann, R., Hassel, J. C., Loquai, C., & Türeci, Ö.
- Affiliations
- BioNTech (Germany) (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Johannes Gutenberg University Mainz (DE)
- Heidelberg University (DE)
- German Cancer Research Center (DE)
- University Hospital Frankfurt (DE)
- ORCID
- Venue
- Nature
- Published
- 2020-07-29
- Volume
- 585
- Issue
- 7823
- Pages
- 107-112
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W3046115489
- Cited by
- 1,052
- References
- 36
- Citations by year
- 2026: 140 · 2025: 204 · 2024: 191 · 2023: 190 · 2022: 174 · 2021: 131 · 2020: 21
- FWCI
- 44.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- RNA vaccines, melanoma, anti-PD-1 therapy, immune checkpoint inhibitors, tumor-associated antigens, cancer immunotherapy, CD4+ T cells, CD8+ T cells, cytotoxic T lymphocyte response
- MeSH terms
- Antigens, Neoplasm, Antineoplastic Agents, Combined Modality Therapy, Humans, Melanoma, Neoplasm Staging, RNA, Neoplasm, T-Lymphocytes, T-Lymphocytes, Cytotoxic, Vaccination, Cancer Vaccines, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
